Literature DB >> 24684031

Higher percentage of in vitro apoptotic cells at time of diagnosis in patients with chronic lymphocytic leukemia indicate earlier treatment requirement: ten years follow up.

Tamara Kravić-Stevović, Andrija Bogdanović, Vladimir Bumbasirević.   

Abstract

INTRODUCTION: Chronic lymphocytic leukemia (CLL) has an extremely variable clinical course. Biological reasons for that wide variation in clinical course and survival rates in CLL patients are not fully understood.
OBJECTIVE: The aim of the study was to evaluate the value of spontaneous apoptosis of CLL cells in vitro determined at presentation of disease, in prediction of treatment requirements and evolution of the CLL.
METHODS: Malignant B cells were isolated from the whole blood of 30 newly diagnosed CLL patients and cultured for 24 hours in RPMI-1640 medium supplemented with 10% of serum obtained from the same CLL patient. Cells were later fixed and processed for embedding in Epon, or cell smears were prepared and stained with TUNEL technique.
RESULTS: Ten-year follow-up revealed that patients with lower percentage of cells in apoptosis at presentation of disease had significant longer time treatment initiation (log rank test p < 0.05). On the contrary, apoptosis of CLL cells was not shown to have significant impact on survival of patients (Kaplan Meier log rank test p > 0.05).
CONCLUSION: The results of this study emphasize the importance of apoptosis of CLL cells at the time of the initial diagnosis in pathobiology of this disease.

Entities:  

Mesh:

Year:  2014        PMID: 24684031     DOI: 10.2298/sarh1402048k

Source DB:  PubMed          Journal:  Srp Arh Celok Lek        ISSN: 0370-8179            Impact factor:   0.207


  1 in total

1.  Association of Bax Expression and Bcl2/Bax Ratio with Clinical and Molecular Prognostic Markers in Chronic Lymphocytic Leukemia.

Authors:  Ksenija Vucicevic; Vladimir Jakovljevic; Natasa Colovic; Natasa Tosic; Tatjana Kostic; Irena Glumac; Sonja Pavlovic; Teodora Karan-Djurasevic; Milica Colovic
Journal:  J Med Biochem       Date:  2016-05-09       Impact factor: 3.402

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.